Abstract library

5 results for "Eggers".
#1553 A Novel In Vitro Model of a Highly Proliferative Pancreatic Neuroendocrine Neoplasia
Introduction: Transformation of well-differentiated neuroendocrine tumors into highly proliferative neuroendocrine neoplasms is a rare, but clinical relevant phenomenon. So far, it is unclear whether these tumors should be treated in analogy to neuroendocrine tumors or as bona fide neuroendocrine carcinoma.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr Joerg Schrader
Authors: Behrang Y, Benten D, Erbes J, Eggers C, ...
Keywords: cell line
#1573 Regulation of Neuroendocrine Differentiation by Growth Factor Induced Proliferation in a Well-differentiated Pancreatic Neuroendocrine Tumor Cell Line
Introduction: The regulation of neuroendocrine differentiation in NET tumor cells is poorly understood. Clinical experience suggests a correlation between proliferation and neuroendocrine de-differentiation.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr Joerg Schrader
Authors: Behrang Y, Benten D, Fahl M, Eggers C, ...
#1867 Establishment of the First Well-Differentiated in Vivo Human Pancreatic Neuroendocrine Tumor Model
Introduction: The development of new therapeutic strategies for cancer patients relies on the in vitro and in vivo testing of novel substances in the pre-clinical setting. So far, this has not been possible for pancreatic neuroendocrine tumors (pNET) due to lack of suitable animal models resembling the disease course in human patients.
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr Joerg Schrader
Authors: Schrader J, Unrau L, Stahl F, Eggers C, ...
Keywords: pNET, insulinoma, SSTR
#1869 Synergistic Effects of Combining Hsp90 and PI3K Inhibitors with Everolimus in Pancreatic Neuroendocrine Tumors
Introduction: The development of the first molecular targeted therapies for neuroendocrine tumors (NET) was a milestone in the treatment of patient. Nevertheless, these therapies eventually fail and patients become resistant to the treatment. One way of escaping this dilemma might be the combination of targeted drugs to prevent resistance development.
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr Joerg Schrader
Authors: Weissmann V, Benten D, Fahl M, Eggers C, ...
#2270 Development of Pre-Clinical NEN Models – Limitations and Opportunities
Introduction: Pre-clinical research in neuroendocrine neoplasia (NEN) has long been impaired by the paucity of NET and NEC cell lines. Furthermore, established models have not been widely available or displayed unusual features (eg. p53 and ras mutations, high proliferation rate).
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr Joerg Schrader
Authors: Schrader J, Benten D, Unrau L, Fahl M, ...
Keywords: cell line
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.